
Non-Hodgkin Lymphoma - Pipeline Insight, 2025
Description
DelveInsight’s, “Non-Hodgkin Lymphoma - Pipeline Insight, 2025,” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Non-Hodgkin Lymphoma: Overview
Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, usually found in the lymph nodes. NHL is not a single disease but rather a group of several closely related cancers, called lymphoid neoplasms. The most recent 2016 revision of the World Health Organization classification of lymphoid neoplasms estimates that there are at least 86 types of NHL. Although the various types of NHL share many common characteristics, they differ in certain features, including their appearance under the microscope, their molecular features and growth patterns, their impact on the body, and how they respond to different types of treatment. NHL is the seventh most common cancer affecting adults in the United States. The incidence of NHL in the United States nearly doubled between 1975 and 2013, and more than 72,000 new cases were estimated to be diagnosed in 2016. Common signs and symptoms of NHL include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss, and lack of energy. It is important to note that most patients with these symptoms do not have lymphoma, as diseases or conditions not related to lymphoma may cause many of these symptoms. A good rule of thumb is to seek medical attention if any of the signs or symptoms last longer than two weeks, or sooner if the symptoms are severe enough to impact daily life.
Non-Hodgkin lymphoma arises either from B cells, T cells, or natural killer cells due to chromosomal translocation or mutation/deletion. Proto-oncogenes are activated by chromosomal translocation, and tumor suppressor genes are inactivated by chromosomal deletion or mutation. The t (14; 18) translocation is the most common chromosomal abnormality in Non-Hodgkin lymphoma. This translocation is most common in follicular lymphoma. The t (11; 14) translocation is associated with mantle cell lymphoma. This results in the overexpression of cyclin D1, a cell cycle regulator. The t (8; 14) translocation of c-myc and heavy chain Ig (14) is associated with Burkitt lymphoma. Alteration in BCL-2 and BCL-6 is associated with diffuse large B-cell lymphoma. Primary CNS lymphoma is mostly associated with HIV/AIDS.
Treatment of Non-Hodgkin lymphoma is based on the type, stage, histopathological features, and symptoms. The most common treatment includes chemotherapy, radiotherapy, immunotherapy, stem cell transplant, and in rare cases, surgery. Chemoimmunotherapy, i.e., rituximab, in combination with chemotherapy, is most commonly used. Radiation is the main treatment for early-stage (I, II). Stage II with bulky disease, stage III, and IV are treated with chemotherapy along with immunotherapy, targeted therapy, and in some cases, radiation therapy.
""Non-Hodgkin Lymphoma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Hodgkin Lymphoma pipeline landscape is provided which includes the disease overview and Non-Hodgkin Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Non-Hodgkin Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Non-Hodgkin Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Hodgkin Lymphoma Emerging Drugs
HMPL-760 is HUTCHMED’s eleventh innovative potential oncology drug candidate to enter clinical develop¬ment. HUTCHMED retains all rights to HMPL-760 worldwide. Currently, the drug is in the Phase I stage of its development for the treatment of non-Hodgkin’s lymphoma.
Further product details are provided in the report……..
Non-Hodgkin Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Non-Hodgkin Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Non-Hodgkin Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Hodgkin Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Hodgkin Lymphoma drugs.
Non-Hodgkin Lymphoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Non-Hodgkin Lymphoma: Overview
Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, usually found in the lymph nodes. NHL is not a single disease but rather a group of several closely related cancers, called lymphoid neoplasms. The most recent 2016 revision of the World Health Organization classification of lymphoid neoplasms estimates that there are at least 86 types of NHL. Although the various types of NHL share many common characteristics, they differ in certain features, including their appearance under the microscope, their molecular features and growth patterns, their impact on the body, and how they respond to different types of treatment. NHL is the seventh most common cancer affecting adults in the United States. The incidence of NHL in the United States nearly doubled between 1975 and 2013, and more than 72,000 new cases were estimated to be diagnosed in 2016. Common signs and symptoms of NHL include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss, and lack of energy. It is important to note that most patients with these symptoms do not have lymphoma, as diseases or conditions not related to lymphoma may cause many of these symptoms. A good rule of thumb is to seek medical attention if any of the signs or symptoms last longer than two weeks, or sooner if the symptoms are severe enough to impact daily life.
Non-Hodgkin lymphoma arises either from B cells, T cells, or natural killer cells due to chromosomal translocation or mutation/deletion. Proto-oncogenes are activated by chromosomal translocation, and tumor suppressor genes are inactivated by chromosomal deletion or mutation. The t (14; 18) translocation is the most common chromosomal abnormality in Non-Hodgkin lymphoma. This translocation is most common in follicular lymphoma. The t (11; 14) translocation is associated with mantle cell lymphoma. This results in the overexpression of cyclin D1, a cell cycle regulator. The t (8; 14) translocation of c-myc and heavy chain Ig (14) is associated with Burkitt lymphoma. Alteration in BCL-2 and BCL-6 is associated with diffuse large B-cell lymphoma. Primary CNS lymphoma is mostly associated with HIV/AIDS.
Treatment of Non-Hodgkin lymphoma is based on the type, stage, histopathological features, and symptoms. The most common treatment includes chemotherapy, radiotherapy, immunotherapy, stem cell transplant, and in rare cases, surgery. Chemoimmunotherapy, i.e., rituximab, in combination with chemotherapy, is most commonly used. Radiation is the main treatment for early-stage (I, II). Stage II with bulky disease, stage III, and IV are treated with chemotherapy along with immunotherapy, targeted therapy, and in some cases, radiation therapy.
""Non-Hodgkin Lymphoma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Hodgkin Lymphoma pipeline landscape is provided which includes the disease overview and Non-Hodgkin Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Non-Hodgkin Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Non-Hodgkin Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Non-Hodgkin Lymphoma.
This segment of the Non-Hodgkin Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Hodgkin Lymphoma Emerging Drugs
- Mosunetuzumab: Hoffmann-la Roche
- Tisagenlecleucel: Novartis
- Capivasertib: AstraZeneca
- BI-1206: BioInvent
- HMPL-760: Hutchmed
HMPL-760 is HUTCHMED’s eleventh innovative potential oncology drug candidate to enter clinical develop¬ment. HUTCHMED retains all rights to HMPL-760 worldwide. Currently, the drug is in the Phase I stage of its development for the treatment of non-Hodgkin’s lymphoma.
Further product details are provided in the report……..
Non-Hodgkin Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Non-Hodgkin Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Non-Hodgkin Lymphoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Non-Hodgkin Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Hodgkin Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Hodgkin Lymphoma drugs.
Non-Hodgkin Lymphoma Report Insights
- Non-Hodgkin Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Non-Hodgkin Lymphoma drugs?
- How many Non-Hodgkin Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Hodgkin Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Hodgkin Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Non-Hodgkin Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- AstraZeneca
- Genentech
- BioInvent
- Genmab
- SystImmune
- Nordic Nanovector
- Pacylex Pharmaceuticals
- Artiva Biotherapeutics, Inc.
- Chipscreen Biosciences, Ltd.
- Timmune Biotech Inc.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Gilead Sciences
- Acerta Pharma BV
- Adagene Inc
- Conjupro Biotherapeutics, Inc.
- Rhizen Pharmaceuticals
- Juventas Cell Therapy Ltd.
- Incyte Corporation
- HUYA Bioscience International
- SecuraBio
- Genor Biopharma Co., Ltd.
- Kyowa Kirin Co., Ltd.
- Antengene Therapeutics Limited
- Regeneron Pharmaceuticals
- Jiangsu HengRui Medicine Co., Ltd.
- Xynomic Pharmaceuticals, Inc.
- BioTheryX, Inc.
- UWELL Biopharma
- Kronos Bio
- Bio-Thera Solutions
- Spectrum Pharmaceuticals, Inc.
- Aptose Biosciences Inc.
- Miltenyi Biomedicine GmbH
- Precision BioSciences, Inc.
- Teneobio, Inc.
- TCR2 Therapeutics
- IGM Biosciences, Inc.
- Tisagenlecleucel
- Capivasertib
- Mosunetuzumab
- BI-1206
- GEN3009
- GNC-038
- Betalutin
- PCLX-001
- AB-101
- Chiauranib
- TriCAR-T-CD19
- PBCAR0191
- CG-806
- TNB-486
- MB-CART2019.1
- TC-110 T Cells
- TQB2303
- IGM-2323
- Magrolimab
- IGN002
- Abexinostat
- BTX-A51
- BAT4306F
- KB-0742
- Welgenaleucel
- SHR1459
- Odronextamab
- ATG-019
- Acalabrutinib
- ADG106
- GB226
- ME-401
- CPO107
- Tenalisib,
- Duvelisib
- CNCT19
- Tafasitamab
- HBI-8000
Table of Contents
450 Pages
- Introduction
- Executive Summary
- Non-Hodgkin Lymphoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Tisagenlecleucel: Novartis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Capivasertib: AstraZeneca
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- BI-1206: BioInvent
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- HMPL-760: Hutchmed
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- Product Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Non-Hodgkin Lymphoma Key Companies
- Non-Hodgkin Lymphoma Key Products
- Non-Hodgkin Lymphoma- Unmet Needs
- Non-Hodgkin Lymphoma- Market Drivers and Barriers
- Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
- Non-Hodgkin Lymphoma Analyst Views
- Non-Hodgkin Lymphoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.